How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Forecasts of explosive AI progress predict that what researchers call recursive self-improvement is on the horizon.  But a new study suggests that it might take a while for us to get there. The ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

National security, unlocked. Each Thursday, host Mary Louise Kelly and a team of NPR correspondents discuss the biggest national security news of the week. With decades of reporting from battlefields ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...